Lu AF82422

Overview
Lu AF82422 is a human antibody that targets alpha-synuclein, a protein that is linked to Parkinson’s disease. Lu AF82422 targets the underlying biology of Parkinson’s disease and aim to treat the disease by slowing or stopping the disease progression. Lu AF82422 was invented by Lundbeck in collaboration with Genmab. Lu AF82422 is being investigated in a Phase I clinical study in both healthy volunteers and patients with Parkinson’s disease.

Clinical studies
Lu AF82422 is being investigated in a Phase I clinical study in healthy volunteers and patients with Parkinson’s disease. For more information, visit clinicaltrials.gov.